Multifaceted Telmisartan: Candidate for new therapeutic approaches
Abstract
Telmisartan is an Angiotensin II type 1 (AT1) receptor blockers (ARBs), that is highly selective for the AT1 receptor and has a long duration of action because of its long terminal elimination half-life1. Telmisartan is considered to be the most potent member of the sartan group because, in addition to AT1R blockade, it strongly activates the antiinflammatory nuclear receptor, peroxisome proliferator-activated receptor γ (PPAR γ)
Downloads
References
Inoue T, Node K. Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother. 2008;9(8):1397-1406. doi:10.1517/14656566.9.8.1397
Wang ZF, Li J, Ma C, Huang C, Li ZQ. Telmisartan ameliorates Aβ oligomer induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells. Biochem Pharmacol. 2020;171:113674. doi:10.1016/j.bcp.2019.113674
Garrido-Gil P, Joglar B, RodriguezPerez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease. J Neuroinflammation. 2012;9:1-16. doi:10.1186/1742-2094-9-38
Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29(4):284-311. doi:10.1016/j.preteyeres.2010.03.003
Saavedra JM. Beneficial effects of Angiotensin II receptor blockers in brain disorders. Pharmacol Res. 2017;125:91- 103. doi:10.1016/j.phrs.2017.06.017
Wang J, Pang T, Hafko R, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates glutamate-induced neurotoxicity: Roles of AT 1 receptor blockade and PPARγ activation. Neuropharmacology. 2014;79:249-261. doi:10.1016/j.neuropharm.2013.11.022
Giese MJ, Speth RC. The ocular renin-angiotensin system: A therapeutic target for the treatment of ocular disease. Pharmacol Ther. 2014;142(1):11-32. doi:10.1016/j.pharmthera.2013.11.002
